4-(hydroxymethyl)-2-isopropyloxazole | 162740-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(hydroxymethyl)-2-isopropyloxazole
• 英文别名: (2-Isopropyl-1,3-oxazol-4-yl)methanol；(2-propan-2-yl-1,3-oxazol-4-yl)methanol
• CAS: 162740-03-6
• 化学式: C₇H₁₁NO₂
• mdl: MFCD16556117
• 分子量: 141.17
• InChiKey: NCXGFKHNRCWGFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲基2-异丙基-1,3-恶唑-4-羧酸酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 以74%的产率得到4-(hydroxymethyl)-2-isopropyloxazole
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+

文献信息

• HETEROCYCLIC COMPOUNDS
  申请人：SHIONOGI & CO., LTD.

  公开号：US20140249159A1

  公开（公告）日：2014-09-04

  The invention relates to compounds of Formula I: wherein Ar 1 , Ar 2 , Ar 3 , L 1 , L 2 , Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及式I的化合物：其中Ar1，Ar2，Ar3，L1，L2，Y，Z和v在说明书中有定义，以及其药学上可接受的衍生物，包括含有式I的化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛，尿失禁，溃疡，炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物中给予式I的化合物或其药学上可接受的衍生物的有效量。
• RETROVIRAL PROTEASE INHIBITING COMPOUNDS
  申请人：ABBOTT LABORATORIES

  公开号：EP0683772A1

  公开（公告）日：1995-11-29
• EP0683772A4
  申请人：——

  公开号：EP0683772A4

  公开（公告）日：1995-09-27
• US5461067A
  申请人：——

  公开号：US5461067A

  公开（公告）日：1995-10-24
• US5621109A
  申请人：——

  公开号：US5621109A

  公开（公告）日：1997-04-15